UCB Pharma licenses mastocytosis drug Gastrocrom to Azur Pharma

By Angela McDaniels

Seattle, Jan. 18 - Azur Pharma Ltd. said it has acquired the U.S. rights to Gastrocrom (cromolyn sodium, usp Oral Concentrate) from UCB Pharma Inc.

Annual sales of Gastrocrom amount to roughly $5 million, according to a company news release. The drug is indicated for the treatment of mastocytosis, a rare disorder characterized by an abnormal accumulation of mast cells in various organ systems.

UCB Pharma is a biopharmaceutical company based in Brussels that specializes in central nervous system disorders, inflammatory diseases and oncology.

Azur Pharma is a privately held pharmaceutical company based in Dublin, Ireland, that develops and markets pharmaceutical products in specialist therapeutic areas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.